Priority Review Vouchers, FDA Funding Win In Omnibus Budget Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
FY 2016 funding bill is much higher than House and Senate appropriations committee totals.
You may also be interested in...
Heritable Genetic Modification Debate May Ignite Again As Technology Advances
CBER Director Peter Marks said the US may have to consider whether to maintain its ban on the practice of creating embryos to include heritable genetic modifications if other countries allow the practice.
US FDA Gains Budget Increase In FY 2017… And Not Through Fees
Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.
Pediatric Rare Disease Voucher Program Faces Expiration
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.